Fast Track is a regulatory milestone that can accelerate development timelines and reduce regulatory risk for PSV359. Key catalysts: Phase 1/2a dose-finding data readouts from the ongoing study are the next major binary events. Monitor for updates on dose-escalation results and any potential for accelerated approval pathway.
Price Chart
Executive Summary
Perspective Therapeutics announced FDA Fast Track Designation for PSV359, its FAP-targeted alpha-particle therapy for solitary fibrous tumors (SFTs), a rare cancer with limited treatment options. The designation may enable more frequent FDA interactions, rolling review, and potential Accelerated Approval or Priority Review. PSV359 is in an ongoing Phase 1/2a study for FAP-positive solid tumors.
Key Facts
- FDA granted Fast Track Designation for PSV359 for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors
- PSV359 is an investigational FAP-targeted alpha-particle therapy in an ongoing Phase 1/2a study (NCT06710756) in advanced FAP-positive solid tumors
- Fast Track may qualify for rolling review, Accelerated Approval, or Priority Review if applicable requirements are met
- SFT is a rare cancer with limited treatment options for advanced disease
- Early human imaging data for PSV359 support strong tumor uptake and fast renal clearance
Financial Impact
No financial figures provided in the filing
Risk Factors
- Fast Track designation does not guarantee approval or that PSV359 will meet clinical endpoints
- Clinical trials may be more costly or take longer than anticipated
- FDA may not grant or may delay approval for product candidates
- Fast Track designation could be subject to withdrawal
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-417384 |
| Document: catx-ex99_1.htm | 0001193125-26-417384 |
| Document: 0001193125-26-417384-index-headers.html | 0001193125-26-417384 |
| Document: 0001193125-26-417384-index.html | 0001193125-26-417384 |
| Document: 0001193125-26-417384.txt | 0001193125-26-417384 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers